Loaec N., Attanasio E., Villiers B., Durieu E., Tahtouh T., Cam M., Davis R. A., Alencar A., Roué Mélanie, Bourguet-Kondracki M. L., Proksch P., Limanton E., Guiheneuf S., Carreaux F., Bazureau J. P., Klautau M., Meijer L. (2017). Marine-derived 2-aminoimidazolone alkaloids. Leucettamine B-related polyandrocarpamines inhibit mammalian and protozoan DYRK & CLK kinases. Marine Drugs, 15 (10), p. art. 316 [15 p.]. ISSN 1660-3397.
Titre du document
Marine-derived 2-aminoimidazolone alkaloids. Leucettamine B-related polyandrocarpamines inhibit mammalian and protozoan DYRK & CLK kinases
Année de publication
2017
Auteurs
Loaec N., Attanasio E., Villiers B., Durieu E., Tahtouh T., Cam M., Davis R. A., Alencar A., Roué Mélanie, Bourguet-Kondracki M. L., Proksch P., Limanton E., Guiheneuf S., Carreaux F., Bazureau J. P., Klautau M., Meijer L.
Source
Marine Drugs, 2017,
15 (10), p. art. 316 [15 p.] ISSN 1660-3397
A large diversity of 2-aminoimidazolone alkaloids is produced by various marine invertebrates, especially by the marine Calcareous sponges Leucetta and Clathrina. The phylogeny of these sponges and the wide scope of 2-aminoimidazolone alkaloids they produce are reviewed in this article. The origin (invertebrate cells, associated microorganisms, or filtered plankton), physiological functions, and natural molecular targets of these alkaloids are largely unknown. Following the identification of leucettamine B as an inhibitor of selected protein kinases, we synthesized a family of analogues, collectively named leucettines, as potent inhibitors of DYRKs (dual-specificity, tyrosine phosphorylation regulated kinases) and CLKs (cdc2-like kinases) and potential pharmacological leads for the treatment of several diseases, including Alzheimer's disease and Down syndrome. We assembled a small library of marine sponge- and ascidian-derived 2-aminoimidazolone alkaloids, along with several synthetic analogues, and tested them on a panel of mammalian and protozoan kinases. Polyandrocarpamines A and B were found to be potent and selective inhibitors of DYRKs and CLKs. They inhibited cyclin D1 phosphorylation on a DYRK1A phosphosite in cultured cells. 2-Aminoimidazolones thus represent a promising chemical scaffold for the design of potential therapeutic drug candidates acting as specific inhibitors of disease-relevant kinases, and possibly other disease-relevant targets.
Plan de classement
Sciences fondamentales / Techniques d'analyse et de recherche [020]
;
Substances naturelles [035]
;
Santé : généralités [050]
Localisation
Fonds IRD [F B010073596]
Identifiant IRD
fdi:010073596
